Christopher Von Seggern - Mar 10, 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Commercial Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 10, 2023
Transactions value $
$0
Form type
4
Date filed
3/14/2023, 04:47 PM
Previous filing
Mar 14, 2022
Next filing
Mar 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +90K $0.00 90K Mar 10, 2023 Common Shares 90K $34.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.